Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Noble Acquires Property with Significant Uranium, Rare Earth, Phosphorus & Silver Mineralization (click to learn more) V.AFM: Record Fy2024 & Q4 ‘24 Tin Production Fy2025 Production Guidance Exploration Success (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ALNY)

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

Business Wire 6 days ago

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Business Wire 12 days ago

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

Business Wire November 27, 2024

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Business Wire November 25, 2024

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Business Wire November 17, 2024

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Business Wire November 4, 2024

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

Business Wire October 31, 2024

Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024

Business Wire October 30, 2024

Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results

Business Wire October 17, 2024
View More News ››

Opinion & Analysis (NDAQ:ALNY)

Investing in biotech stocks is not for amateurs (CLDX) (NPSP)

Marc Lichtenfeld January 17, 2014
View More Opinion ››

Bullboard Posts (NDAQ:ALNY)

Alnylam (ALNY): A Promising Biotech Poised for Transformativ

http://beyondspx.com/2024/07/31/alnylam-alny-a-promising-biotech-poised-for-transformative-growth/
MikeTester - August 2, 2024

ALNY Price Target Alert: $260.00. Issued by Evercore ISI

Just In: $ALNY ALNY Price Target Alert: $260.00. Issued by Evercore ISI2024-06-25 09:00:09 ET Liisa Bayko from Evercore ISI issued a...
whytestocks - June 25, 2024

Buy Recommendation Issued On ALNY By Citigroup

BREAKING NEWS: $ALNY Buy Recommendation Issued On ALNY By Citigroup2024-06-25 07:15:05 ET Citigroup analyst issues BUY recommendation...
whytestocks - June 25, 2024

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year

News; $ALNY Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity...
whytestocks - February 15, 2024

RNA Interference (RNAi) Drug Delivery Market Size 2022-27

According to IMARC Group’s latest report, titled “RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size...
edwardebreen15 - August 22, 2022

Next multibagger

https://stockhouse.com/news/press-releases/2019/01/31/patient-five-cancer-free-twelve-months-after-single-anti-cancer-treatment
goregil - February 14, 2019
View more Bullboard ››

NexTech3D.AI Corp.

NexTech3D.AI Corp.

NexTech3D.AI Corp. is a diversified augmented reality (AR), artificial intelligence (AI) technology company. The Company ...
View More »